Welcome : Guest

Pharming Group N.V. (The Netherlands) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Pharming Group N.V., which is principally involved in Pharmaceuticals Business. Illustrated with 33 tables, the report showcases the company's sales performance, key markets and market position as against its competitors operating in the industry.

Code: PCP-08403
Price: $1650
Company Type: Public
Pages: 35
Date: November 2016
Market Data Tables: 33

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
  PHARMING GROUP N.V. (THE NETHERLANDS) (Complete Report)Pages : 35|$ 1650.00
1. COMPANY SNIPPETS......1
2. MAJOR PRODUCTS AND SERVICES......2
3. SALES DATA......3
Table 1: Pharming Group N.V.'s Sales by Geographic Region Worldwide (2014-2015) in Percentage for United States, Europe, and Rest of the World......3
4. MARKET OVERVIEW......4
Hemophilia A......4
Table 2: Hemophilia Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Hemophilia A, Hemophilia B, Inhibitor, and Von Willebrand Disease......4
Table 3: On-Demand (Moderate Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......5
Table 4: On-Demand (Severe Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......6
Table 5: Haemophilia Patient Population by Category Worldwide (2015) - Percentage Market Share Breakdown by Volume for Haemophilia A (Factor VIII Deficiency) and Haemophilia B (Factor IX Deficiency)......7
Continuous Prophylaxis......8
Table 6: Continuous Prophylaxis Treatment (Severe) for Hemophilia A Patients by Age Group Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......8
Table 7: Continuous Prophylaxis (Moderate) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......9
Intermittent Prophylaxis......10
Table 8: Intermittent Prophylaxis (Moderate Patient Equivalent) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......10
Table 9: Intermittent Prophylaxis (Severe Patient Equivalent) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......11
Protease Inhibitors......12
Table 10: Hepatitis C Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Immuno Modulator, Polymerase Inhibitor, Protease Inhibitors, and Others* (Includes Ribavirin)......12
Table 11: HIV Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)/ Nucleoside Reverse Transcriptase Inhibitor (NRTI) Fixed Dose Combination (FDC), Nucleoside Reverse Transcriptase Inhibitor (NRTI)/Retroviral Integrase/CYP3A, Nucleoside Reverse Transcriptase Inhibitor (NRTIs), Protease Inhibitors, Retroviral Integrase (IN), and Others* (Includes NNRTIs)......13
Table 12: Protease Inhibitors Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for APTIVUS, KALETRA, PREZISTA, and REYATAZ......14
Table 13: Hepatitis C Virus Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Immuno-Modulator, Polymerase Inhibitor, Protease Inhibitors, Ribavirin, and Others......15
Factor VIII (FVIII)......16
Table 14: Factor VIII (FVIII) Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Plasma-Derived (PD FVIII) and Standard r-FVIII (Recombinant FVIII)......16
Table 15: Plasma Derivatives Market by Segment Worldwide (2014) - Percentage Share Breakdown by Value for Albumin, Alpha-1 Proteinase Inhibitor (A1PI), Hyperimmune, Intravenous Immunoglobulin (IVIG), Plasma-Derived Factor VIII (PDFVIII) & Willebrand Factor (WFactor), Polymeric Immunoglobulin Receptor, and Others......17
Table 16: Plasma Market by Product Worldwide (2015) - Percentage Breakdown by Value for Albumin, Factor IX, Factor VIII, Hyperimmunes, Intravenous Immunoglobulin (IVIG), and Others......18
Table 17: Plasma Market by Products (excluding Recombinant Factors) Worldwide (2015) - Percentage Share Breakdown by Value for Albumin, Factor VIII, Intravenous Immunoglobulin (IVIG) and Others......19
Table 18: Plasma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Coagulation Factor IX, Coagulation Factor VIII, Fibrinogen, Human Albumin, Intravenous Immunoglobulin (IVIG), Specific Immunoglobulin and Others......20
Table 19: Plasma Products Consumption by Type in China (2015) - Percentage Share Breakdown by Volume for Albumin, Factor VIII, Hyperimmunes (IM&IV), and Intravenous Immunoglobulin (IVIG)......21
Table 20: Plasma Market by Segment in China (2015) - Percentage Share Breakdown by Value for Alpha-1 proteinase inhibitor (A1PI), Coagulation Factor IX, Coagulation Factor VIII, Fibrinogen, Human Albumin, Immunoglobulin for Intramuscular Injection, Intravenous Immunoglobulin (IVIG), Prothrombin Complex, and Specific Immunoglobulin......22
Table 21: Factor VIII (FVIII) Market by Category in the US (2015) - Percentage Share Breakdown by Volume Sales for Plasma-Derived (PD) FVIII and Standard r-FVIII (Recombinant FVIII)......23
Table 22: Factor VIII (FVIII) Market by Category in the US (2015) - Percentage Share Breakdown by Value Sales for Plasma-Derived (PD FVIII) and Standard r-FVIII (Recombinant FVIII)......24
Table 23: Plasma Products Consumption by Type in the US (2015) - Percentage Share Breakdown by Volume for Albumin, Factor IX (Plasma), Factor VIII, Hyperimmunes (IM&IV), and Intravenous Immunoglobulin (IVIG), and Others......25
Alpha-Glucosidase Inhibitors......26
Table 24: Diabetes Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Insulin Type‐1 Diabetes, Insulin Type‐2 Diabetes, Dipeptidyl Peptidase 4, (DPP4), Glucagon-like Peptide-1 (GLP‐1), Dipeptidyl Peptidase 4, (DPP4) + Biguanide, and Others* (includes Sodium-Glucose Co-Transporter-2 (SGLT2), Biguanide, Sulfonylurea, Alpha-Glucosidase Inhibitors, Peroxisome Proliferator-Activated Receptor (PPAR)......26
Table 25: Non-Insulin Anti-Diabetic Drugs Market by Product in China (2015) - Percentage Share Breakdown by Value for Biguanides, Glucosidase Inhibitors, Nateglinide, Sulfonylurea and Others......27
Table 26: Diabetic Drugs Market by Category in China (2015) - Percentage Share Breakdown by Value for Biguanides, Glinide, Insulin, Sulfonylureas, α-glucosidase Inhibitor, and Others......28
5. COMPETITIVE LANDSCAPE......29
Haemophilia A......29
Table 27: Market Shares of Leading Haemophilia A Treatment Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value Sales for Baxter International Inc. (Advate), Bayer AG (Kogenate), CSL Behring, LLC (Helixate), Pfizer, Inc. (Refacto) and Others......29
Pancreatic Enzyme......30
Table 28: Market Shares of Leading Pancreatic Enzyme Manufacturers in the US (2015) - Percentage Share Breakdown by Prescriptions for Abbott Laboratories, Alcan Ohler GmbH, Aptalis, Johnson and Johnson, and Other......30
Factor VIII (With Recombinant Factor)......31
Table 29: Market Shares of Leading Factor VIII (Without Recombinant Factor) Companies in China (2014) - Percentage Breakdown by Value for China Biologic Products, Inc., Green Cross Corporation, Hualan Biological Engineering, Inc., and Shanghai RAAS Blood Products Co., Ltd.......31
Table 30: Market Shares of Leading Factor VIII (With Recombinant Factor) Companies in China (2014) - Percentage Breakdown by Value for Bayer AG, China Biologic Products, Inc., Green Cross Corporation, Hualan Biological Engineering, Inc., and Shanghai RAAS Blood Products Co., Ltd.......32
Table 31: Market Shares of Leading Factor VIII Providers in China (2015) - Percentage Breakdown by Value for China Biologic Products, Inc., Green Cross (China) Co., Ltd., Shanghai RAAS Blood Products Co., Ltd., and Others......33
Table 32: Market Shares of Leading Factor VIII Providers in the US (2015) - Percentage Breakdown by Value for Baxter International Inc., CSL Limited, Grifols, S.A., and Kedrion S.p.A......34
6. COMPANY FACTS......35
Table 33: Pharming Group N.V.'s Sales by Geographic Region Worldwide (2013-2014) in Percentage for United States, Europe and Rest of the World......35